...
首页> 外文期刊>Hypertension: An Official Journal of the American Heart Association >Role of Endothelium-Derived Hyperpolarizing Factor in ACE Inhibitor-Induced Renal Vasodilation in Vivo
【24h】

Role of Endothelium-Derived Hyperpolarizing Factor in ACE Inhibitor-Induced Renal Vasodilation in Vivo

机译:内皮衍生的超极化因子在ACE抑制剂诱导的体内肾脏血管舒张中的作用

获取原文

摘要

Although the angiotensin-converting enzyme (ACE) inhibitor-induced bradykinin enhances nitric oxide (NO) release, bradykinin may also stimulate the production of an additional vasodilator, endothelium-derived hyperpolarizing factor (EDHF). This study examined the role of EDHF in mediating the NO-independent action of ACE inhibitors in canine renal microcirculation in vivo. We used intravital CCD camera videomicroscopy that allowed direct visualization of renal microcirculation in superficial and juxtamedullary nephrons in an in vivo, in situ, and relatively intact setting. In the presence of E4177 (an angiotensin receptor blocker), cilazaprilat (30 μg/kg) had no effect on diameter of superficial afferent arterioles (Aff), but it increased renal contents of bradykinin and nitrate plus nitrite, and it elicited dilation of juxtamedullary Aff (from 24.0±0.2 to 28.2±0.8 μm), juxtamedullary efferent arterioles (Eff) (from 24.2±0.2 to 28.0±0.8 μm), and superficial Eff (from 18.2±0.2 to 19.7±0.2 μm). These changes in diameters were prevented by Nα-adamantaneacetyl-d-Arg-[Hyp3,Thi5,8,D-Phe7]bradykinin, a bradykinin receptor antagonist. The pretreatment with nitro-l-arginine methylester (l-NAME) plus E4177 eliminated the dilator response of juxtamedullary/superficial Eff and the increase in renal nitrate plus nitrite levels induced by cilazaprilat. In contrast, in the presence of E4177+l-NAME, cilazaprilat still caused 8%±3% dilation of juxtamedullary Aff, which was completely eliminated by proadifen, a cytochrome-P450 and KCa channel blocker. Collectively, the ACE inhibitor exerts multiple vasodilator mechanisms, including the inhibition of angiotensin II formation; blockade of angiotensin II activity appears to be a dominant mechanism in superficial Aff, whereas the bradykinin-induced NO acts on superficial Eff and juxtamedullary Aff/Eff. Furthermore, a putative EDHF is an additional mechanism for the ACE inhibitor-induced vasodilation of juxtamedullary Aff in vivo.
机译:尽管血管紧张素转换酶(ACE)抑制剂诱导的缓激肽增强了一氧化氮(NO)的释放,但是缓激肽也可能刺激额外的血管扩张剂,即内皮衍生的超极化因子(EDHF)的产生。这项研究检查了EDHF在体内犬肾微循环中介导ACE抑制剂不依赖NO的作用。我们使用了活体内的CCD摄像机视频显微镜,可以在体内,原位和相对完整的环境中直接观察浅表和近髓肾中肾微循环的情况。在存在E4177(一种血管紧张素受体阻滞剂)的情况下,西拉普利拉(30μg/ kg)对浅表小动脉(Aff)的直径无影响,但会增加缓激肽和硝酸盐及亚硝酸盐的肾脏含量,并引起近髓质扩张Aff(从24.0±0.2到28.2±0.8μm),近四肢传出小动脉(Eff)(从24.2±0.2到28.0±0.8μm)和浅表Eff(从18.2±0.2到19.7±0.2μm)。这些直径的变化被缓激肽受体拮抗剂Nα-金刚烷乙酰基-d-Arg- [Hyp3,Thi5,8,D-Phe7]缓激肽所阻止。用硝基-1-精氨酸甲酯(l-NAME)加上E4177进行的预处理消除了近足/浅表Eff的扩张反应,以及西拉普利拉引起的肾硝酸盐和亚硝酸盐水平的增加。相反,在存在E4177 + 1-NAME的情况下,西拉普利拉仍然引起近髓Aff的8%±3%扩张,而后者被细胞色素P450和KCa通道阻滞剂proadifen完全消除了。 ACE抑制剂共同发挥多种血管扩张剂机制,包括抑制血管紧张素II的形成。阻断血管紧张素II活性似乎是浅表Aff的主要机制,而缓激肽诱导的NO作用于浅表Eff和近髓性Aff / Eff。此外,推定的EDHF是体内ACE抑制剂诱导的近髓Aff血管舒张的另一机制。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号